Literature DB >> 26843116

Serum Androgen Levels and Sexual Function Before and One Year After Treatment of Uterine Cervical Cancer: A Pilot Study.

Åsa H Everhov1, Angelique Flöter Rådestad2, Tommy Nyberg3, Karin E Smedby4, Karin Bergmark5, Angelica Lindén Hirschberg2.   

Abstract

INTRODUCTION: Radiotherapy or radical hysterectomy with salpingo-oophorectomy (SOE) as treatment for uterine cervical cancer causes estrogen deprivation in premenopausal women. The effects on androgen production have rarely been examined but could be relevant for survivors of cervical cancer because insufficiency has been associated with low sexual function. AIM: To investigate the effects of pelvic radiotherapy, hysterectomy with SOE, or surgery without SOE on androgen levels and to explore potential associations with sexual function.
METHODS: Patients with cervical cancer (N = 60) were prospectively examined through blood sampling and questionnaires before and 1 year after treatments. MAIN OUTCOME MEASURES: Serum testosterone (measured by liquid chromatography and tandem mass spectrometry), sex hormone-binding globulin, androstenedione, dehydroepiandrosterone sulfate, follicle-stimulating hormone, luteinizing hormone, and estradiol levels and Female Sexual Function Index scores.
RESULTS: In women treated with radiotherapy (n = 38), median total and free testosterone levels were significantly decreased at 1-year follow-up compared with baseline in premenopausal women (n = 16; total testosterone -29%, P = .01; free testosterone -22%, P = .007) and postmenopausal women (n = 22; total testosterone -25%, P = .03; free testosterone -29%, P = .03). Androstenedione was decreased in premenopausal women only and dehydroepiandrosterone sulfate was decreased in postmenopausal women only after radiotherapy. In women treated with hysterectomy and SOE (n = 10), testosterone levels were lower but not significantly lower, and there was no change in those having surgery without SOE (n = 12). Female Sexual Function Index scores lower than 26.5 in sexually active women were reported by 80% 1 year after radiotherapy, by 44% after hysterectomy with SOE, and by 40% after surgery without SOE, with no significant differences compared with baseline values. No direct correlation between androgen levels and Female Sexual Function Index scores were found at 1-year follow-up.
CONCLUSION: Total and free testosterone levels decreased slightly but significantly after pelvic radiotherapy in pre- and postmenopausal women. The clinical importance of this decrease is unclear, but androgen levels were not directly related to sexual function in this pilot setting.
Copyright © 2016 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androstenedione; Female Sexual Function Index; Radiotherapy; Sexual Function; Testosterone; Uterine Cervical Cancer

Mesh:

Substances:

Year:  2016        PMID: 26843116     DOI: 10.1016/j.jsxm.2015.12.022

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  3 in total

1.  Oncology Section EDGE Task Force on Cancer: A systematic review of patient-reported measures for sexual dysfunction.

Authors:  Meryl Alappattu; Shana E Harrington; Alexandra Hill; Amanda Roscow; Alicia Jeffrey
Journal:  Rehabil Oncol       Date:  2017-07

2.  Effect of radiotherapy for rectal cancer on ovarian androgen production.

Authors:  J Segelman; C Buchli; A Svanström Röjvall; P Matthiessen; S Arver; M Bottai; M Ahlberg; R Jasuja; A Flöter-Rådestad; A Martling
Journal:  Br J Surg       Date:  2018-09-12       Impact factor: 6.939

3.  Topical estrogen, testosterone, and vaginal dilator in the prevention of vaginal stenosis after radiotherapy in women with cervical cancer: a randomized clinical trial.

Authors:  Jumara Martins; Ana Francisca Vaz; Regina Celia Grion; Lúcia Costa-Paiva; Luiz Francisco Baccaro
Journal:  BMC Cancer       Date:  2021-06-10       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.